Cell-based therapies for tissue fibrosis

Research output: Contribution to journalReview ArticleResearchpeer-review

10 Citations (Scopus)

Abstract

The development of tissue fibrosis in the context of a wound-healing response to injury is common to many chronic diseases. Unregulated or persistent fibrogenesis may lead to structural and functional changes in organs that increase the risk of significant morbidity and mortality. We will explore the natural history, epidemiology, and pathogenesis of fibrotic disease affecting the lungs, kidneys, and liver as dysfunction of these organs is responsible for a substantial proportion of global mortality. For many patients with end-stage disease, organ transplantation is the only effective therapy to prolong life. However, not all patients are candidates for the major surgical interventions and life-long immunosuppression required for a successful outcome and donor organs may not be available to meet the clinical need. We will provide an overview of the latest treatment strategies for these conditions and will focus on stem or progenitor cell-based therapies for which there is substantial pre-clinical evidence based on animal models as well as early phase clinical trials of cell-based therapy in man.

Original languageEnglish
Article number633
Number of pages8
JournalFrontiers in Pharmacology
Volume8
DOIs
Publication statusPublished - 22 Sep 2017

Keywords

  • Cell therapy
  • Fibrosis
  • Mesenchymal stem cells
  • Progenitor cells
  • Stem cells and regenerative medicine

Cite this

@article{b605bced91584e939ddec51ac98fcc25,
title = "Cell-based therapies for tissue fibrosis",
abstract = "The development of tissue fibrosis in the context of a wound-healing response to injury is common to many chronic diseases. Unregulated or persistent fibrogenesis may lead to structural and functional changes in organs that increase the risk of significant morbidity and mortality. We will explore the natural history, epidemiology, and pathogenesis of fibrotic disease affecting the lungs, kidneys, and liver as dysfunction of these organs is responsible for a substantial proportion of global mortality. For many patients with end-stage disease, organ transplantation is the only effective therapy to prolong life. However, not all patients are candidates for the major surgical interventions and life-long immunosuppression required for a successful outcome and donor organs may not be available to meet the clinical need. We will provide an overview of the latest treatment strategies for these conditions and will focus on stem or progenitor cell-based therapies for which there is substantial pre-clinical evidence based on animal models as well as early phase clinical trials of cell-based therapy in man.",
keywords = "Cell therapy, Fibrosis, Mesenchymal stem cells, Progenitor cells, Stem cells and regenerative medicine",
author = "Rebecca Lim and Ricardo, {Sharon D.} and William Sievert",
year = "2017",
month = "9",
day = "22",
doi = "10.3389/fphar.2017.00633",
language = "English",
volume = "8",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media",

}

Cell-based therapies for tissue fibrosis. / Lim, Rebecca; Ricardo, Sharon D.; Sievert, William.

In: Frontiers in Pharmacology, Vol. 8, 633, 22.09.2017.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Cell-based therapies for tissue fibrosis

AU - Lim, Rebecca

AU - Ricardo, Sharon D.

AU - Sievert, William

PY - 2017/9/22

Y1 - 2017/9/22

N2 - The development of tissue fibrosis in the context of a wound-healing response to injury is common to many chronic diseases. Unregulated or persistent fibrogenesis may lead to structural and functional changes in organs that increase the risk of significant morbidity and mortality. We will explore the natural history, epidemiology, and pathogenesis of fibrotic disease affecting the lungs, kidneys, and liver as dysfunction of these organs is responsible for a substantial proportion of global mortality. For many patients with end-stage disease, organ transplantation is the only effective therapy to prolong life. However, not all patients are candidates for the major surgical interventions and life-long immunosuppression required for a successful outcome and donor organs may not be available to meet the clinical need. We will provide an overview of the latest treatment strategies for these conditions and will focus on stem or progenitor cell-based therapies for which there is substantial pre-clinical evidence based on animal models as well as early phase clinical trials of cell-based therapy in man.

AB - The development of tissue fibrosis in the context of a wound-healing response to injury is common to many chronic diseases. Unregulated or persistent fibrogenesis may lead to structural and functional changes in organs that increase the risk of significant morbidity and mortality. We will explore the natural history, epidemiology, and pathogenesis of fibrotic disease affecting the lungs, kidneys, and liver as dysfunction of these organs is responsible for a substantial proportion of global mortality. For many patients with end-stage disease, organ transplantation is the only effective therapy to prolong life. However, not all patients are candidates for the major surgical interventions and life-long immunosuppression required for a successful outcome and donor organs may not be available to meet the clinical need. We will provide an overview of the latest treatment strategies for these conditions and will focus on stem or progenitor cell-based therapies for which there is substantial pre-clinical evidence based on animal models as well as early phase clinical trials of cell-based therapy in man.

KW - Cell therapy

KW - Fibrosis

KW - Mesenchymal stem cells

KW - Progenitor cells

KW - Stem cells and regenerative medicine

UR - http://www.scopus.com/inward/record.url?scp=85030101187&partnerID=8YFLogxK

U2 - 10.3389/fphar.2017.00633

DO - 10.3389/fphar.2017.00633

M3 - Review Article

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - 633

ER -